^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CCNE1 amplification

    i
    Other names: CCNE1, CCNE, Cyclin E1
    Entrez ID:
    898
    Related biomarkers:
    Expression
    Mutation
    Others
    11ms
    (VELA) Study of BLU-222 in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=366, Active, not recruiting, Blueprint Medicines Corporation | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • CCNE1 (Cyclin E1)
    |
    HER-2 negative • CCNE1 amplification
    |
    carboplatin • Kisqali (ribociclib) • fulvestrant • cirtociclib (BLU-222)
    11ms
    RP-6306 in Patients With Advanced Cancer (clinicaltrials.gov)
    P2, N=78, Recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2025 --> May 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CCNE1 (Cyclin E1) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation • CCNE1 amplification • UGT1A1*28 • UGT1A1*1*1
    |
    Herceptin (trastuzumab) • gemcitabine • 5-fluorouracil • irinotecan • leucovorin calcium • lunresertib (RP-6306) • camonsertib (RP-3500)
    11ms
    Co-Amplification Of CCNE1 And AKT2 As Prognostic Biomarker And Therapeutic Target In Tubo-Ovarian High-Grade Serous Carcinoma (ESGO 2025)
    Drug sensitivity assays showed increased sensitivity of these co-amplified cell lines to the pan-AKT inhibitor capivasertib compared to non-amplified cell lines.Conclusion Co-amplification of CCNE1 and AKT2 is a marker of poor prognosis and HRP in HGSC. AKT2 dependency in co-amplified cells suggests a potential therapeutic target, with capivasertib showing promise for treatment.
    BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CD8 (cluster of differentiation 8) • CCNE1 (Cyclin E1) • AKT2 (V-akt murine thymoma viral oncogene homolog 2)
    |
    CCNE1 amplification
    |
    Truqap (capivasertib)
    12ms
    Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib. (PubMed, Genome Med)
    These analyses provide valuable insight into patterns of genomic instability and potential drivers of HRD, besides BRCAm, in ovarian cancer and will help guide future research into the potential clinical effectiveness of anti-cancer treatments in ovarian cancer, including PARP inhibitors as well as other precision oncology agents.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • CCNE1 (Cyclin E1) • PALB2 (Partner and localizer of BRCA2) • BRCA (Breast cancer early onset) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D)
    |
    PIK3CA mutation • HRD • CCNE1 amplification • PIK3CA amplification • BRIP1 mutation • RAD51C mutation • RAD51D mutation
    |
    Lynparza (olaparib)
    12ms
    Enhancing the detection of clinically relevant biomarkers in advanced uterine and tubo-ovarian carcinomas through genome-wide analysis. (PubMed, Pathol Res Pract)
    Comprehensive genomic profiling of advanced-stage TOC and UC via WGS reveals key biomarkers and therapeutic targets, enhancing diagnostic accuracy and advancing personalized medicine in gynecological cancers.
    Journal • Tumor mutational burden • BRCA Biomarker • PARP Biomarker • Metastases
    |
    TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • CCNE1 (Cyclin E1) • CDK12 (Cyclin dependent kinase 12)
    |
    TMB-H • HRD • BRCA wild-type • CCNE1 amplification
    12ms
    BISCAY: Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P1, N=117, Active, not recruiting, AstraZeneca | Trial completion date: Jun 2024 --> Mar 2025
    Trial completion date
    |
    HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • FGFR (Fibroblast Growth Factor Receptor) • CD8 (cluster of differentiation 8) • CCNE1 (Cyclin E1) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)
    |
    PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)
    1year
    Palbociclib and Pembrolizumab in Central Nervous System Metastases (clinicaltrials.gov)
    P2, N=45, Recruiting, Massachusetts General Hospital | N=30 --> 45 | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Sep 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • CCND2 (Cyclin D2) • CCND3 (Cyclin D3)
    |
    CCNE1 amplification • CCND1 amplification • CDK4 amplification
    |
    Keytruda (pembrolizumab) • Ibrance (palbociclib)
    1year
    ACQUIRED CYCLIN D AMPLIFICATION IS A MECHANISM FOR RESISTANCE TO CDK4/6 INHIBITORS IN DEDIFFERENTIATED LIPOSARCOMA (CTOS 2024)
    We reviewed demographic data, treatment histories, and overall response rates (ORR). We identified five patients with DDLPS who were treated with CDK4/6i, palbociclib and abemaciclib. In untreated WD/DD LPS, baseline alterations in cyclin D are rare. Our analysis revealed that three patients with DDLPS acquired either cyclin D1 or cyclin D2 amplification in progressing samples following treatment with CDK4/6i. Unlike breast cancer, where cyclin E1 amplification is a well-established driver of resistance to CDK4/6i, these findings suggest a potential role for cyclin D amplification in acquired resistance in LPS.
    PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • RB1 (RB Transcriptional Corepressor 1) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • AURKA (Aurora kinase A) • CCND2 (Cyclin D2)
    |
    HR positive • HER-2 negative • CCNE1 amplification • RB1 mutation • CCND1 amplification • CCNE1 overexpression • CDK4 amplification • EGFR positive • MDM2 amplification + CDK4 amplification
    |
    MSK-IMPACT
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib)
    1year
    Development of a novel treatment based on PKMYT1 inhibition for cisplatin-resistant bladder cancer with miR-424-5p-dependent cyclin E1 amplification. (PubMed, BMC Cancer)
    Overall, our findings provided insights into the development of novel therapeutic strategies for CDDP-R BC.
    Journal
    |
    CCNE1 (Cyclin E1) • MIR424 (MicroRNA 424) • PKMYT1 (Protein Kinase Membrane Associated Tyrosine/Threonine 1)
    |
    CCNE1 amplification
    |
    cisplatin
    1year
    Targeting CDK2 to combat drug resistance in cancer therapy. (PubMed, Future Oncol)
    Specifically, amplifications of CCNE1/CCNE2 are associated with resistance to targeted therapies, immunotherapy, endocrine therapies and chemo/radiotherapy. Given CDK2's involvement in resistance mechanisms, investigating its role presents promising opportunities for developing novel strategies to combat resistance and improve treatment outcomes.
    Review • Journal
    |
    CCNE1 (Cyclin E1) • CDK2 (Cyclin-dependent kinase 2) • CCNE2 (Cyclin E2)
    |
    CCNE1 amplification
    1year
    Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Sep 2025
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CD4 (CD4 Molecule)
    |
    BRCA2 mutation • BRCA1 mutation • CCNE1 amplification • BRIP1 mutation • FANCA mutation
    |
    Lynparza (olaparib) • adavosertib (AZD1775)
    1year
    Race- associated molecular differences in uterine serous carcinoma. (PubMed, Front Oncol)
    Identifying actionable mutations in this high unmet need population is crucial to improving outcomes among Black patients with uterine malignancy. Development of new targeted-therapies will need to keep these alterations at the forefront as trials are being designed.
    Journal
    |
    CCNE1 (Cyclin E1)
    |
    CCNE1 amplification • MTOR mutation
    |
    FoundationOne® CDx